secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-01-27T23:59:59+00:00
Accession:  0001193125-26-023387
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for ATTRv-PN; MAGNITUDE hold ongoing
--------------------------------------------------------------------------------

- FDA removed clinical hold on IND for MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv-PN, imposed Oct 29, 2025 after Grade 4 liver event and patient death.
- Intellia to resume patient enrollment with enhanced liver safety monitoring; target enrollment increased from ~50 to ~60 patients.
- FDA engagement ongoing for clinical hold on MAGNITUDE Phase 3 trial for ATTR-CM; no update on path forward yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526023387/0001193125-26-023387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526023387/d29201d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-023387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer